Virtuix Holdings Inc. and Rutgers University are researching AI-assisted therapy for neurodivergent individuals using the Omni One omni-directional treadmill. The collaboration evaluates how immersive, full-body virtual reality improves therapeutic engagement for children with autism compared to traditional methods.
CEO Jan Goetgeluk stated the partnership enables new categories of user engagement beyond traditional VR experiences. Virtuix clarified that its primary focus remains on consumer entertainment and defense applications despite this expansion into healthcare.
The company's stock currently trades near its 52-week low. Shares have declined 86% year-to-date.